CardiASC, 50 mg 60 pcs

CardIASC is an anti-aggregative.

Pharmacodynamics

. The mechanism of antiplatelet action of acetylsalicylic acid (ASA) is based on irreversible inhibition of COX-1, resulting in blocked synthesis of thromboxane A2 and suppressed platelet aggregation. The antiplatelet effect develops even after a low dose of the drug and lasts for 7 days after a single dose. It is believed that ASA has other mechanisms of platelet aggregation inhibition, which expands the field of its use in various vascular diseases. At high doses, ASK also has anti-inflammatory, antipyretic and analgesic effects.

Pharmacokinetics

Assoc is quickly and completely absorbed from the GI tract after oral administration. ASK is partially metabolized during absorption. During and after absorption ASA is converted to the main metabolite, salicylic acid, which is metabolized mainly in the liver under the influence of enzymes to form metabolites such as phenylsalicylate, salicylic acid glucuronide and salicyluric acid found in many tissues and in urine. In women, the metabolic process is slower (lower serum enzyme activity). Tmax of ASA in blood plasma is 10-20 minutes after oral administration, and of salicylic acid – 0.3-2 hours.

Due to the fact that the tablets are covered with an acid-resistant coating, ASK is not released in the stomach (the coating effectively blocks dissolution of the drug in the stomach), but in the alkaline environment of the duodenum. Thus, absorption of Asc in the form of tablets coated with an enteric coating is delayed by 3-6 hours compared to conventional (without such a coating) tablets. Asc and salicylic acid are bound to blood plasma proteins (from 66 to 93% depending on the dose) and are rapidly distributed in the body. Salicylic acid passes through the placenta and into the breast milk.

The excretion of salicylic acid is dose-dependent because its metabolism is limited by the enzymatic system. T1/2 is from 2-3 hours when using ASA in low doses and up to 16 hours when using the drug in high doses (common doses of acetylsalicylic acid as an analgesic). Unlike other salicylates, non-hydrolyzed ASA does not accumulate in the blood serum when taking the drug repeatedly. Salicylic acid and its metabolites are excreted by the kidneys. In patients with normal renal function 80-100% of a single dose of the drug is excreted by kidneys within 24-72 hours.

Indications

Active ingredient

Composition

Active ingredient:

acetylsalicylic acid 50 mg;

Associates:

Stearic acid;

Corn starch;

lactose monohydrate (milk sugar);

hydrogenated castor oil;

povidone (plasdon K90 or collidone 90F);

polysorbate (tween 80);

MCC;

Film coating:

metacrylic acid and ethyl acrylate copolymer 1:1 (collicut MAE 100P); macrogol and polyvinyl alcohol copolymer (collicut IR); copovidone (plasdon S630); triethylcitrate; talc; titanium dioxide.

How to take, the dosage

CardiASC should be taken orally before meals with plenty of fluid.
CardiASC is intended for long-term use. The duration of therapy is determined by the attending physician.

Prophylaxis for suspected acute myocardial infarction: 100-200 mg/day or 300 mg every other day (the first tablet should be chewed for faster absorption).

Prevention of first-onset acute myocardial infarction in the presence of risk factors: 100 mg daily or 300 mg every other day.

Prevention of recurrent myocardial infarction, unstable angina pectoris, prevention of stroke and transient impairment of cerebral circulation, prevention of thromboembolic complications after surgical operations or invasive studies: 100-300 mg daily

Prevention of deep vein thrombosis and pulmonary artery and branch thromboembolism: 100-200 mg daily or 300 mg every other day.

Interaction

When used concomitantly, CardIASC enhances the effects of methotrexate by reducing its renal clearance and displacement from plasma protein binding.

When used concomitantly, CardIASC potentiates the effects of heparin and indirect anticoagulants due to disruption of platelet function and displacement of indirect anticoagulants from plasma protein binding.

CardIASC when used in combination enhances the effect of thrombolytic and antiplatelet drugs (including ticlopidine).

CardIASC increases plasma concentrations of digoxin by reducing renal excretion and enhances its effects.

CardIASC increases the effect of hypoglycemic drugs (insulin and sulfonylurea derivatives) due to the hypoglycemic effect of acetylsalicylic acid (at high doses) and displacing sulfonylurea derivatives from binding to plasma proteins.

CardIASC enhances the effect of valproic acid by displacing the latter from plasma protein binding.

When used concomitantly, CardIASC attenuates the effects of uricosuric drugs (benzbromaron) due to competitive tubular elimination of uric acid.

Concomitant use of GCS enhances excretion of salicylates and attenuates their effects.

In concomitant use with ethanol an additive effect is noted.

Contraindications

Side effects

Allergic reactions: urticaria, Quincke’s edema.

Gastrointestinal tract:nausea, heartburn, vomiting, abdominal pain, gastric and duodenal ulcers, including perforative, gastrointestinal bleeding, increased activity of “liver” enzymes.

In the respiratory system: bronchospasm.

From the immune system:anaphylactic reactions.

Hematopoietic system disorders:anemia (rare), increased bleeding.

From the central nervous system: dizziness, tinnitus.

Overdose

Symptoms of an overdose of moderate severity: Nausea, vomiting, tinnitus, impaired hearing, dizziness, confusion.

Treatment: reducing the dose of the drug.

Serious overdose symptoms: fever, hyperventilation, ketoacidosis, respiratory alkalosis, coma, cardiovascular and respiratory failure, severe hypoglycemia.

Treatment: Immediate hospitalization in specialized departments for emergency therapy – gastric lavage, determination of acid-base status, alkaline and forced alkaline diuresis, hemodialysis, administration of solutions, activated carbon, symptomatic therapy. When performing alkaline diuresis, it is necessary to achieve pH values between 7.5 and 8. Forced alkaline diuresis should be performed when plasma concentration of salicylates is more than 500 mg/l (3.6 mmol/l) in adults and 300 mg/l (2.2 mmol/l) in children.

Similarities